For the quarter ending 2025-09-30, IRD made $3,079,000 in revenue. -$17,454,000 in net income. Net profit margin of -566.87%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| License and collaborations revenue | 3,079,000 | 2,882,000 | 4,370,000 | 2,375,000 |
| General and administrative | 4,981,000 | 5,766,000 | 6,346,000 | 5,107,000 |
| Acquired in-process research and development | - | - | - | 9,333,333.333 |
| Research and development | 6,409,000 | 6,022,000 | 7,953,000 | 5,956,333.333 |
| Total operating expenses | 11,390,000 | 11,788,000 | 14,299,000 | 20,396,666.667 |
| Loss from operations | -8,311,000 | -8,906,000 | -9,929,000 | -18,021,666.667 |
| Fair value change in warrant and other derivative liabilities | -9,525,000 | 917,000 | 2,805,000 | 18,000 |
| Financing costs | 0 | -35,000 | 1,372,000 | - |
| Interest expense | 68,000 | - | - | - |
| Other income, net | 450,000 | 534,000 | 302,000 | 1,329,000 |
| Loss before income taxes | -17,454,000 | -7,420,000 | -8,194,000 | -16,668,666.667 |
| Benefit (provision) for income taxes | 0 | 0 | - | - |
| Net loss | -17,454,000 | -7,420,000 | -8,194,000 | -16,668,666.667 |
| Other comprehensive loss, net of tax | 0 | 0 | - | - |
| Comprehensive loss | -17,454,000 | -7,420,000 | -8,194,000 | -16,668,666.667 |
| Basic (in dollars per share) | -0.25 | -0.12 | -0.24 | -0.62 |
| Basic (in shares) | 70,636,887 | 63,376,392 | 33,884,920 | 190,148.667 |
| Diluted (in dollars per share) | -0.25 | -0.12 | -0.24 | -0.62 |
| Diluted (in shares) | 70,636,887 | 63,376,392 | 33,884,920 | 190,148.667 |
Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. (IRD)